AG
PACB icon

Aperio Group’s Pacific Biosciences PACB Stock Holding History

Aperio Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$3.02M Sell
116,226
-7,262
-6% -$123K 0.01% 1052
2020
Q3 		$1.22M Buy
123,488
+1,140
+0.9% +$6.56K ﹤0.01% 1347
2020
Q2 		$422K Buy
122,348
+19,173
+19% +$65.3K ﹤0.01% 1853
2020
Q1 		$316K Buy
103,175
+7,681
+8% +$31.5K ﹤0.01% 1875
2019
Q4 		$491K Buy
95,494
+8,538
+10% +$43.4K ﹤0.01% 1806
2019
Q3 		$449K Buy
86,956
+10,710
+14% +$59.9K ﹤0.01% 1815
2019
Q2 		$461K Buy
76,246
+12,844
+20% +$90.1K ﹤0.01% 1822
2019
Q1 		$458K Buy
63,402
+15,140
+31% +$110K ﹤0.01% 1797
2018
Q4 		$357K Sell
48,262
-460
-0.9% -$2.92K ﹤0.01% 1869
2018
Q3 		$264K Sell
48,722
-1,015
-2% -$4.36K ﹤0.01% 2073
2018
Q2 		$177K Sell
49,737
-383
-0.8% -$1.06K ﹤0.01% 2181
2018
Q1 		$103K Buy
50,120
+21,775
+77% +$56.5K ﹤0.01% 2214
2017
Q4 		$75K Sell
28,345
-14,051
-33% -$49.2K ﹤0.01% 2218
2017
Q3 		$223K Buy
42,396
+21,766
+106% +$93.6K ﹤0.01% 2076
2017
Q2 		$73K Sell
20,630
-1,851
-8% -$7.46K ﹤0.01% 2191
2017
Q1 		$116K Buy
22,481
+9,117
+68% +$44.6K ﹤0.01% 2101
2016
Q4 		$51K Sell
13,364
-14,108
-51% -$103K ﹤0.01% 2104
2016
Q3 		$246K Buy
27,472
+171
+0.6% +$1.43K ﹤0.01% 1825
2016
Q2 		$192K Buy
27,301
+1,826
+7% +$16.7K ﹤0.01% 1873
2016
Q1 		$217K Sell
25,475
-1,275
-5% -$12.5K ﹤0.01% 1836
2015
Q4 		$351K Buy
26,750
+2,489
+10% +$22.3K ﹤0.01% 1524
2015
Q3 		$89K Buy
24,261
+11,454
+89% +$56K ﹤0.01% 1869
2015
Q2 		$74K Hold
12,807
– – ﹤0.01% 1968
2015
Q1 		$75K Buy
12,807
+138
+1% +$952 ﹤0.01% 1929
2014
Q4 		$99K Hold
12,669
– – ﹤0.01% 1834
2014
Q3 		$62K Sell
12,669
-885
-7% -$4.63K ﹤0.01% 1713
2014
Q2 		$84K Buy
13,554
+731
+6% +$3.66K ﹤0.01% 1691
2014
Q1 		$69K Buy
+12,823
New +$81K ﹤0.01% 1991
2013
Q4 		– Sell
-12,081
Closed -$55.5K – 1940
2013
Q3 		$67K Buy
+12,081
New +$41.9K ﹤0.01% 1759

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Aperio Group's PACB Position: Q4 2020 in Review

Aperio Group reduced its Pacific Biosciences (PACB) stake by 5.9% in Q4 2020, selling an estimated $123K and leaving 116,226 shares worth $3.02M. The position accounts for 0.01% of the portfolio, ranked #1052.

Aperio Group first reported a position in PACB in Q3 2013 and has held it in 29 quarters since. 210 funds tracked by Wall St. Rank hold PACB as of Q4 2020.

  • Aperio Group held 116,226 shares of Pacific Biosciences worth $3.02M as of Q4 2020.
  • Aperio Group sold 7,262 Pacific Biosciences shares in Q4 2020, an estimated $123K.
  • Pacific Biosciences made up 0.01% of Aperio Group's portfolio in Q4 2020, its #1052 holding.
  • Aperio Group first reported a position in Pacific Biosciences in Q3 2013 and has held it in 29 quarters since.
  • 210 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.